CLYM
Climb Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.52
+6.37%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-24.1%
Return on equity
-23.4%
Return on assets
-26.9%
Return on invested capital
0.00x
Asset turnover
-$52.7M
Cash from operations
$3.19
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026